Summary： This study aimed to evaluate the effects of Pinl inhibitor Juglone on proliferation, migration and the angiogenic ability of breast cancer cell line MCF7Adr. MCF7Adr ceils were cultured and sepa- rately trea...Summary： This study aimed to evaluate the effects of Pinl inhibitor Juglone on proliferation, migration and the angiogenic ability of breast cancer cell line MCF7Adr. MCF7Adr ceils were cultured and sepa- rately treated with Pinl inhibitor Juglone （treatment group） and DMEM without drug （control group）. The cell cycle was examined by flow cytometry. Cell migration was measured by wound-healing assay. Cyclin E protein content was detected by Western blotting. The angiogenesis factor vascular endothelial growth factor （VEGF） in cell media was determined by enzyme linked immunosorbent assay. The re- suits showed that the percentage of cells in GJM phase in treatment group was significantly higher than that in control group （25.5% vs. 10.1%, P〈0.05）, and that in G0/G1 phase and S stage in treatment group was significantly lower than that in control group （40.5% vs. 48.2%, and 33.7% vs. 41.7%, P〈0：05）. Cyclin E protein content in treatment group was significantly lower than that in control group （39.2±7.4 vs. 100±23.1, P〈0.05）. （A0-A24）/A0 value in treatment group was significantly lower than that in control group （23.9±3.8 vs. 100±14.4, P〈0.05）. VEGF-A, -B, and -C contents in cell media of treatment group were significantly lower than those in control group （P〈0.05）. It was suggested that Pinl inhibitor Juglone can effectively inhibit the proliferation, migration and the angiogenic ability of MCF7Adr cells, and can be used as an alternative drug therapy for breast cancer.展开更多
文摘Summary： This study aimed to evaluate the effects of Pinl inhibitor Juglone on proliferation, migration and the angiogenic ability of breast cancer cell line MCF7Adr. MCF7Adr ceils were cultured and sepa- rately treated with Pinl inhibitor Juglone （treatment group） and DMEM without drug （control group）. The cell cycle was examined by flow cytometry. Cell migration was measured by wound-healing assay. Cyclin E protein content was detected by Western blotting. The angiogenesis factor vascular endothelial growth factor （VEGF） in cell media was determined by enzyme linked immunosorbent assay. The re- suits showed that the percentage of cells in GJM phase in treatment group was significantly higher than that in control group （25.5% vs. 10.1%, P〈0.05）, and that in G0/G1 phase and S stage in treatment group was significantly lower than that in control group （40.5% vs. 48.2%, and 33.7% vs. 41.7%, P〈0：05）. Cyclin E protein content in treatment group was significantly lower than that in control group （39.2±7.4 vs. 100±23.1, P〈0.05）. （A0-A24）/A0 value in treatment group was significantly lower than that in control group （23.9±3.8 vs. 100±14.4, P〈0.05）. VEGF-A, -B, and -C contents in cell media of treatment group were significantly lower than those in control group （P〈0.05）. It was suggested that Pinl inhibitor Juglone can effectively inhibit the proliferation, migration and the angiogenic ability of MCF7Adr cells, and can be used as an alternative drug therapy for breast cancer.
